Living longer on the land : a health program that works : an economic evaluation of the sustainable farm families program by Boymal, Jonathan et al.
	 	
	
 
 
This is the published version:  
 
Boymal,	Jonathan,	Rogers,	Patricia,	Brumby,	Susan	and	Willder,	Stuart	2007,	Living	longer	on	the	
land	:	a	health	program	that	works	:	an	economic	evaluation	of	the	sustainable	farm	families	
program,	Rural	Industries	Research	and	Development	Corporation,	Barton,	ACT.	
	
	
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30033836	
	
	
Reproduced	with	the	kind	permission	of	the	copyright	owner.		
	
Copyright	:	2007,	RIRADC	
  
 
 
 
 
 
 
 
 
 
Living Longer on the Land 
A health program that works 
 
An economic evaluation of the Sustainable Farm Families 
Program 
 
 
 
 
by Jonathan Boymal, Patricia Rogers, Susan Brumby and Stuart Willder 
 
 
 
 
October 2007 
 
 
 
 
 
RIRDC Publication No 07/094 
RIRDC Project No WDH-3A 
 
 ii 
 
© 2007  Rural Industries Research and Development Corporation.  
All rights reserved.    
 
 
ISBN 1 74151 491 6 
ISSN 1440-6845 
 
Living Longer on the Land: An economic evaluation of a health program that works for rural Australians 
Publication No. 07/094 
Project No. WDH-3A 
 
The information contained in this publication is intended for general use to assist public knowledge and discussion and 
to help improve the development of sustainable regions. You must not rely on any information contained in this 
publication without taking specialist advice relevant to your particular circumstances.  
While reasonable care has been taken in preparing this publication to ensure that information is true and correct, the 
Commonwealth of Australia gives no assurance as to the accuracy of any information in this publication. 
The Commonwealth of Australia, the Rural Industries Research and Development Corporation (RIRDC), the authors or 
contributors expressly disclaim, to the maximum extent permitted by law, all responsibility and liability to any person, 
arising directly or indirectly from any act or omission, or for any consequences of any such act or omission, made in 
reliance on the contents of this publication, whether or not caused by any negligence on the part of the Commonwealth 
of Australia, RIRDC, the authors or contributors.. 
The Commonwealth of Australia does not necessarily endorse the views in this publication. 
This publication is copyright. Apart from any use as permitted under the Copyright Act 1968, all other rights are 
reserved. However, wide dissemination is encouraged. Requests and inquiries concerning reproduction and rights 
should be addressed to the RIRDC Publications Manager on phone 02 6271 4165 
 
 
 
Researcher Contact Details 
Ms. Susan Brumby 
Western District Health Service 
PO Box 283 
Hamilton  VIC  3300 
 
Phone: 03 5551 8460   
Fax:  03 5572 5371  
Email:  susan.brumby@wdhs.net  
 
 
 
In submitting this report, the researcher has agreed to RIRDC publishing this material in its edited form. 
 
RIRDC Contact Details 
Rural Industries Research and Development Corporation 
Level 2, 15 National Circuit  
BARTON   ACT   2600 
PO Box 4776   
KINGSTON   ACT   2604  
 
Phone:  02 6271 4100 
Fax:       02 6271 4199 
Email:   rirdc@rirdc.gov.au. 
Web:  http://www.rirdc.gov.au 
 
 
 
 
 
 
 
Published in October 2007 
iii 
Foreword 
 
By urban standards, the general health of rural people is poor. Rural and farming populations have 
above average rates of premature morbidity and mortality through heart disease, cancer and suicide. 
Health related behaviours are an important determinant of avoidable mortality and morbidity. 
Improvements in farming family health can be expected to generate benefits that include: 
• reduced morbidity and premature mortality 
• healthier farming communities 
• improved workforce health 
• greater farm output  
• financial benefits to all three levels of government related to reduced health and other service 
expenditure.  
 
It is in this context that the Sustainable Farm Families (SFF) project of the Western District Health 
Service, Hamilton, Victoria has been working with farming families in a number of industries 
including dairy, cotton, sugar and grains since 2003. The SFF project is designed to influence 
farmers’ behaviour with respect to their family health, wellbeing and safety by focussing on the 
human resource in the triple bottom line.  
 
This report describes a benefit:cost analysis of the Sustainable Farm Families Program. It found that 
as a result of improved health outcomes, the SFF project was cost effective in reducing mortality 
associated with Type 2 diabetes and cardiovascular disease amongst the participants, providing cost 
savings to government, and to the community. 
 
The results of this research will inform resource allocation decisions by local, state and federal policy 
makers to ensure the greatest possible contribution to improving rural health from a limited budget, 
by suggesting that interventions designed to influence health related behaviours may be particularly 
effective. The report also provides a methodology to guide benefit:cost evaluations of the 
effectiveness of other health interventions to improve the sustainability of the farming workforce 
through better health.  
 
This project was funded by the RIRDC-managed Joint Research Venture for Farm Health and Safety 
with the vision of enhancing the well being and productivity in rural industries through improved 
occupational health and safety status of Australian agriculture delivered by the establishment of safe 
systems of work on farms.  The partners in the Joint Venture are Grains Research and Development 
Corporation, Sugar Research and Development Corporation, Meat and Livestock Australia, 
Australian Wool Innovation, Cotton Research and Development Corporation and Rural Industries 
Research and Development Corporation. 
 
This report is an addition to RIRDC’s diverse range of over 1600 research publications. 
 
Most of our publications are available for viewing, downloading or purchasing online through our 
website: 
 
• downloads at www.rirdc.gov.au/fullreports/index.html 
• purchases at www.rirdc.gov.au/eshop 
 
Peter O’Brien 
Managing Director 
Rural Industries Research and Development Corporation 
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Executive Summary 
 
What the report is about 
This report presents the results of an economic evaluation of the Sustainable Farm Families (SFF) 
project, which is designed to influence farmers’ behaviours with respect to health, safety and well 
being.  The report sets out four different types of economic analysis: 
• cost analysis 
• cost-effectiveness analysis 
• cost-utility analysis 
• cost-savings analysis. 
 
Who is the report targeted at? 
The report is targeted at those involved in rural health, agricultural industries and the rural workforce, 
particularly those with responsibilities for policy development and resource allocation. It provides 
specific information about a particular project and provides a methodology that could be adapted and 
further developed for similar projects. 
 
Background 
The general health of rural people is, by urban standards, poor, with rural and farming populations 
having above average rates of premature morbidity and mortality through heart disease, cancer and 
suicide. Improvements in rural health can be expected to generate benefits that include: greater farm 
output, financial benefits to all three levels of government related to reduced health and other service 
expenditure and healthier farming communities and reduced morbidity and premature mortality. 
The SFF project is designed for people who have 
farmed for more than five years and are aged 
between 18 and 75 years. It is open to any member 
of a farming family business and participants are self 
-selecting. The SFF project engages with farming 
families through annual workshops, newsletters and 
their industry associations. Participants are tracked 
over three years using baseline health data, pre and 
post-knowledge surveys and personal action plans. 
 
Aims 
The aim of the project was to provide an economic 
model of the impact and cost effectiveness of the 
Sustainable Farm Families program which can then 
be used in a number of industries, for example sugar, dairy and cotton. 
 
Methods used  
Data were collected on 128 participants involved in broad acre farming in five locations: Benalla, 
Clare (SA), Hamilton, Horsham and Swan Hill. Evidence of changes in clinical indicators came from 
three annual health assessments which provided data on fasting cholesterol; fasting blood sugar; four 
indicators related to obesity – body mass index, waist hip ratio, waist measurement, and percentage of 
fat in body mass; systolic and diastolic blood pressure; and pulse rate. In addition, the evaluation is 
based on analysis of the costs of implementing the project (from records and reported purchases), 
evidence about changes in behaviour (from self-report), projected changes to morbidity and mortality 
(based on published research on risk factors), and on the estimated value of these changes in terms of 
quality of life (based on published research) and cost-savings (based on published research about the 
costs of cardiovascular events and diabetes). 
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Figure 1  Overview of evidence and economic analyses of the SFF project 
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Results 
The total costs of running the project, consisting of project delivery costs, direct costs to participants, 
and costs of additional health service utilisation, were calculated as $141,189 for 128 participants 
across five sites. Participants in the SFF project reported behaviour changes in terms of eating 
healthier food, undertaking more exercise and safer farming work practices. 
 
Measured clinical indicators, including body mass index, systolic blood pressure, total cholesterol 
level, waist circumference and waist hip ratio, showed statistically significant (p ≤ 0.05) average 
improvements over 12 and 24 months. Costs per risk factor eliminated ranged from $1,426 (total 
cholesterol) to $4,706 (weight). 
 
On the basis of these changes in clinical indicators, it is projected that eight cases of diabetes per year 
and two cardio-vascular events over 10 years have been avoided. 
 
In order to facilitate a comparison of the SFF project with other health projects that may involve 
qualitatively different outputs, a ‘Quality Adjusted Life Year’ (QALY) outcome measure was used. A 
Quality Adjusted Life Year is a measure of the additional length of life produced by health 
interventions, adjusted for the quality of life. Perfect health is rated as 1; death is rated as zero; 
different health states are rated with reference to these – usually some number between 0 and 1 but a 
negative score for health states was considered to be worse than death! QALYs can be added and 
compared – so that an intervention that leads to 10 extra years of life rated as 0.5 in quality would 
produce a total outcome of 5 QALYs.  
Published weights in the literature were utilised for this report. In order to explicitly compare QALYs 
that are gained at different points in time, future QALYs are ‘factored down’ so that they can be 
expressed in present values. This ‘factoring down’ is known as ‘discounting’, and is consistent with 
the treatment of future benefits and costs in all economic evaluations. 
The total gain in discounted QALYs over 10 years from the SFF project is calculated to be 4.33. This 
means that the equivalent of nearly 4 ½ years of perfect health. 
Where half of the total costs of the SFF project are attributed to these outcomes (and half to other 
outcomes), the cost per discounted QALY gained is $16,304. These costs per QALY do not include 
downstream cost savings. The SFF project therefore achieves the $40,000 per QALY acceptability 
threshold (used as a standard for drug approvals) largely due to its contribution to reduced incidence 
of Type 2 diabetes. 
Cost savings from the predicted reduced incidence of Type 2 diabetes (and subsequent savings in 
related health care) over 10 years are estimated at $154,929, which exceeds the total cost of the SFF 
project itself. This indicates that the SFF project generates net cost savings, even if we only consider 
its outcome in terms of diabetes incidence. 
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Implications for relevant stakeholders 
The economic analysis indicates that the SFF project is good value for money in terms of changing 
behaviours and thus improving health outcomes for rural Australians and saving government’s 
money. This suggests it may be worthwhile expanding the project beyond the study group. 
 
In order for the economic analysis to be undertaken a robust methodology was developed that can be 
readily adapted to other projects that seek to influence health-related behaviours. 
 
This report will assist in informing resource allocation decisions to ensure the greatest contribution to 
rural health improvement possible from a limited budget, by determining whether interventions 
designed to influence health related behaviours are particularly effective. Evaluation results will be 
used to inform future implementation of the SFF project and to inform the development of other 
projects to reduce morbidity and mortality among farming families. 
 
Recommendations 
Based on the findings of this report, it is recommended that: 
• behavioural change projects related to health such as the Sustainable Farming Families project be 
continued and extended 
• the methodology developed in this project be further developed and used to evaluate similar 
projects 
• further investigation of other health outcomes of the SFF should be documented and analysed 
• participants should be reassessed in five years to determine whether improvements in clinical 
indicators have been maintained and possibly to gather evidence about morbidity and mortality. 
 
 1 
Introduction 
 
The research project had two purposes:  
• to undertake an economic evaluation of the Sustainable Farm Families (SFF) project, assessing its 
cost-effectiveness, cost-utility, and cost-savings, and  
• to develop a methodology for future economic evaluations. 
The report sets out the methodology for the economic evaluation. It begins with an overview of the 
different types of economic evaluation – cost-effectiveness, cost-utility, cost-benefit and cost-savings. 
It then provides details of the data sources and methods of analysis used. This section is intended to 
provide guidance for future economic evaluations of similar projects. 
 
This is followed by an overview of the SFF project, including the rationale and need for the project 
and a description of its activities and outcomes in terms of reported changes in health behaviours and 
measures of changes in clinical indicators. 
 
An economic evaluation of the SFF project in terms of changes in clinical indicators and their 
consequences is then described. It begins by calculating the costs of the project, and the cost per 
participant and per participant for whom three years of data are available. 
 
Three types of economic evaluation are then presented.  Cost-effectiveness calculates the cost of 
reducing or eliminating each risk factor, using evidence of changes in these indicators from the 
reported project outcomes. Cost utility calculates the cost for each QALY (quality-adjusted life year), 
using projections of changes in morbidity and mortality, specifically cardio-vascular events, death 
from cardio-vascular events, and Type 2 diabetes, based on observed changes in clinical indicators. 
Cost savings analysis estimates the net cost to government taking into account the costs of the project 
and the savings in terms of reduced health care costs. 
 
In conclusion, there is a summary of the economic evaluation and a discussion of the implications of 
the methodology for future evaluations of projects. 
2 
Methodology 
 
This section sets out the different types of economic analysis, describes the overall research design, 
discusses the evidence to support the argument that the SFF project contributed to the observed 
changes in clinical indicators, and describes the sources of evidence and the methods of analysis. 
 
Types of economic analysis 
 
Economic evaluation is essentially concerned with a comparison of the benefits and costs of an 
intervention. Different economic evaluation approaches essentially reflect different approaches to the 
measurement and valuation of costs and benefits. 
 
Costs can be understood in terms of: 
• financial values of the resources used, including money, in-kind support, and time 
• foregone opportunities in not using these resources for other purposes 
• any negative outcomes (either expressed in qualitative terms or converted to monetary terms). 
 
This economic evaluation analyses the cost of the intervention in terms of the first of these options, 
the total resources used, expressed in financial terms. 
 
Benefits can be understood in terms of: 
• achievement of a specific short-term or long-term outcome, such as specific reductions in clinical 
indicators 
• achievement of outcomes in terms of the quality and quantity of additional years of life produced  
• achievement of outcomes expressed in monetary terms 
• savings due to avoiding negative outcomes or costs (either expressed qualitatively or in monetary 
terms). 
The quality and quantity of quality adjusted life years is expressed in terms of quality-adjusted life 
years (QALY). A QALY is a measure of the additional length of life produced by health 
interventions, adjusted for the quality of life.  Perfect health is rated as 1; death is rated as zero; 
different health states are rated with reference to these – usually, these are some number between 0 
and 1 but health states that are considered to be worse than death will have a negative score.  For 
example, based on the self-reports of respondents with Type 2 diabetes, the DiabCost study (Colagiuri 
et al., 2003) reported that macrovascular complications (such as heart disease, stroke and peripheral 
vascular disease) reduced respondents’ quality of life score by 0.16, while microvascular 
complications (such as nerve damage, kidney disease and vision disorders) reduced respondents’ 
quality of life score by 0.2. QALYs can be added and compared – so that an intervention that leads to 
10 extra years of life rated as 0.5 in quality would produce a total outcome of 5 QALYs. An 
intervention may increase QALYs by extending life, increasing the quality of life, or some 
combination of the two. 
In addition to these benefits that relate to the direct health outcomes for participants, there are likely 
to be additional health benefits to family members and to the wider community – for example, the 
cost of volunteer time to look after ill people at home or to support them in hospital. It is not, 
however, common to capture these wider influences in economic evaluations, and measuring 
individual benefit will, for many health interventions, represent an acceptable simplification. This 
does mean that the total benefits of these interventions are likely to be understated. In this economic 
evaluation, potential broader effects of the SFF project that extend beyond the direct health outcomes 
of participants are not included in the analysis, including reported strengthening of community 
capacity. 
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Four commonly recognised economic evaluation models reflect different approaches to the 
measurement and valuation of benefits. 
 
Table 1  A typology of economic analysis 
 
Cost-effectiveness 
analysis 
The relationship between program costs and program 
effectiveness, in terms of a specific short-term or long-term 
outcome.    
Cost-utility analysis The relationship between costs and outcomes expressed in 
terms of the Quality Adjusted Life Year – (QALY) which 
takes into account both quantity and quality of extended life. 
Cost-benefit analysis The measurement of both costs and benefits in monetary 
terms. 
Cost-savings analysis The measurement of net fiscal savings as a result of a program 
Cost-effectiveness analysis is useful for comparing alternative ways of pursuing a specific objective. 
Cost-effectiveness analysis does not require program outcomes to be expressed in dollar terms, but in 
terms of an appropriate health status attribute. This represents an intermediate step in cost-benefit 
analysis. This type of analysis is most commonly applied where a number of alternative health 
programs, designed to contribute to the same health objective are to be compared, such as a number of 
programs targeted at smoking cessation or weight control. Final health outcome measures of a more 
generic nature are also commonly used in cost-effectiveness analysis, such as fatal events avoided, 
change in risk of death or non-fatal events and life years ‘saved'. There are numerous examples of 
cost-effectiveness analysis of health programs, which illustrate how in practice the implementation 
issues are addressed (see for example, Segal, et al, 2005, Farquhar, et al, 1990; Hatziandreu, et al, 
1988; Lindgren et. al, 2003; Munro, et al, 2002).  
Cost-utility analysis is a particular type of cost-effectiveness analysis, where the unit of outcome is 
the quality adjusted life year (QALY), which is obtained by multiplying a quality of life index by the 
number of calendar years of life. The quality of life index comes from ratings from a sample of 
people.  This method of evaluation requires measurement of the change in health status of participants 
attributable to the intervention. This approach is attractive in that it offers a single, universally 
applicable description of health outcome, broadening the range of health interventions which can be 
directly compared. The QALY encompasses all aspects of health status in a single measure, which 
can then be related to program cost to yield a dollar cost/quality adjusted life year. Cost/QALY can be 
compared across any health programs to establish relative performance. A program yielding a lower 
cost/QALY would be preferred to a program costing more per QALY gain.   
Cost-benefit analysis addresses the question of whether, or to what extent, any policy or program is 
worth pursuing. It does this by identifying all costs and benefits and weighing one against the other. 
In its pure form this requires the translation of all effects, cost and benefits into dollar values. 
Performance can then simply be expressed in dollars, either as a net present value estimate, or rate of 
return. Results of the program under review can be compared with rates of return or net present value 
achievable from other types of investments/programs to establish relative performance. Cost-benefit 
analysis has been unpopular in the evaluation of health programs due to concerns about the ability to 
translate health outcomes, like enhanced quality of life or reduction in risk of premature death, into 
dollars.  This type of analysis is not included in the economic evaluation of SFF. 
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Cost savings analysis investigates whether public expenditures for such programs could be justified, 
at least in part, by the savings to government they generate. If the savings generated by such programs 
are greater than their costs, government fiscal support for such programs may be considered a 
worthwhile investment of public funds, regardless of the need to demonstrate other broader benefits to 
society. Care is needed to ensure that apparent cost-savings are not in fact due to cost-shifting to other 
parties or to other levels of government. 
Research design and analysis of causal contribution 
 
Evidence of the impact of the SFF project was based on a before-and-after longitudinal observational 
study, with no control group. 
 
The study provided evidence of changes in clinical indicators, but not of changes in morbidity and 
mortality, which would require a longer timeframe.  Instead projected changes in morbidity and 
mortality were calculated using research evidence linking these with clinical indicators. This is an 
established practice in the health evaluation literature when considering preventative interventions, as 
it is unusual for participants to be followed up for the requisite time for an expected change in risk of 
death or quality of life to be able to be observed. 
 
Figure 2  Overview of evidence for causal contribution of the SFF project 
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The study provides evidence to support the conclusion that the SFF project contributed to observed 
changes in clinical indicators.  Although the design does not include a control group, support for 
causal contribution comes from participants’ accounts of their health-related behaviour changes as 
part of their personal action plans, which they attributed to participation in the project. 
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More convincing evidence of the causal contribution of the SFF project comes from systematic 
investigation of alternative explanations for the observed changes in clinical indicators, drawing on 
Campbell and Stanley’s (1963) classic list of threats to internal validity: 
• history 
• maturation 
• repeated testing 
• instrumentation 
• regression to the mean  
• experimental mortality  
• selection  
• interactions between selection and other factors. 
History refers to another event during the period that is the actual cause of the observed changes.  No 
other similar project or event was reported during the period of implementation of SFF that could 
have produced these changes. Some broader social marketing campaigns around specific diseases or 
nutrition may have contributed to creating a conducive environment for change, but since these have 
occurred at other times before SFF was implemented without leading to improvements in clinical 
indicators, it does not seem likely that they have caused the changes.   
Maturation refers to natural development that leads to performance improvement – most commonly 
seen in children who are likely to grow, and perform better due to maturation.  In the case of the SFF 
project, the reverse is more likely – that with increasing age, participants would be more likely to 
have worse clinical indicators. 
Repeated testing can have an effect where knowledge or behaviour appears to improve due to 
familiarity with testing procedures.  Measures used to collect evidence of clinical indicators are not 
susceptible to this threat as they are objective measures of physical conditions. 
Instrumentation refers to the impact of changes in the continuity of instruments used to collect data.  
This is more likely to be an issue where there have been changes in the personnel collecting data, 
where research scales have been used over a long time and need to be reformed, or where evidence 
comes from methods such as observer ratings which can vary over time.  Measures used to collect 
evidence of clinical indicators are not susceptible to this threat due to the stability of the measures, the 
continuity of staff undertaking the measurements, and the relatively short time frame. 
Regression to the mean is a threat where participants have been selected on the basis of lower than 
average performance on an indicator with considerable error in its measurement.  A number of those 
with performance measured just below the average are likely to have higher levels of actual 
performance than measured performance.  The next time they are measured, if the measured 
performance more accurately reflects their actual performance, the result will be an increase in 
measured performance which can be mistaken for an increase in actual performance.    
Experimental mortality refers to differential drop-out rates between groups that are being compared, 
as well as to mortality in terms of actual death.  For example, if participants for whom the SFF project 
was not successful dropped out, average clinical indicators among those who finished would be better 
than the average of those who started even if there were no actual changes for individual participants.  
For this reason, the analysis of outcomes only includes changes among the 97 participants who 
completed the project and provided three years of outcome data.   
Selection can threaten validity if two groups which are being compared are different in terms of an 
important variable which by itself could explain the difference in observed performance.  Although 
there is no explicit comparison between SFF participants and another group, there is an implicit 
comparison with those who chose not to participate.  Clearly, participants in SFF might be expected 
to be more highly motivated to make changes in health behaviours than non-participants, even though 
some participants were apparently initially reluctant to attend.  However this is not sufficient to 
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invalidate the findings, as there is not evidence that this higher level of motivation had translated into 
sustained behaviour changes before participation in the SFF project. 
Selection interactions refer to interactions between the selection to participate and the other threats.   
No such interactions were identified.  
This analysis demonstrates that a credible argument for causal contribution of the SFF project can be 
made despite the absence of a common design for impact evaluation, the randomised control trial 
(RCT). RCTs are difficult to implement both logistically and ethically, particularly in small rural 
communities and in projects with small evaluation budgets.  
 
In addition, for projects such as the SFF project, the motivation of participants is likely to be a 
legitimate contributory factor, unlike the impact of interventions such as water fluoridisation, where 
active participation is not required for the intervention to work. 
 
Data sources for evidence of outcomes 
 
Participants 
Out of a total of 128 participants, there were 104 project completers. Although year one and year 
three data were sourced for these 104 participants, complete three-year data were sourced for only 97 
out of the 128 project participants, including all outcome measures related to clinical and behavioural 
parameters. 
 
Evidence of behaviour change 
Participants reported changes in their health behaviours using a behaviourally-anchored self-
achievement scale in terms of: 
• healthier eating 
• increased exercise 
• health checks 
• safer work practices. 
 
As there was no external validation of these self-reports, the focus of the evaluation is on changes in 
clinical indicators.  These do however provide evidence to support the causal contribution of the SFF 
project to the observed changes in clinical indicators. 
 
Evidence of changes in clinical indicators 
The SFF project included measurement of clinical indicators as part of its implementation. Evidence 
of changes in clinical indicators came from three annual health assessments, which provided data on: 
• fasting cholesterol 
• fasting blood sugar 
• four indicators related to obesity - body mass index, waist hip ratio,  waist measurement, and 
percentage of fat in body mass 
• systolic and diastolic blood pressure 
• pulse rate. 
 
Evidence of projected impact on morbidity and mortality 
The analysis has focused on the likely consequences of the project in terms of changes in the 
incidence of cardiovascular disease and Type 2 diabetes. The project also demonstrated changes in 
stress, work safety practices, alcohol consumption and undertaking first aid courses. These were not 
included in the economic analysis due to limitations in the data available about all participants and in 
the research literature about their implications for morbidity and mortality. 
 
The projected impact on morbidity and mortality has been calculated using clinical parameters as 
predictors. This is commonly applied in the economic evaluation literature and relies on the 
application of published risk equations derived from large-scale cohort studies (eg, Anderson et al, 
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1991; Griffin et al 2000). These published risk equations provide valuable information as to the 
determinants of disease-specific mortality or morbidity. 
 
For the purposes of estimating changes in the incidence of cardiovascular disease and Type 2 
diabetes, it was assumed that any changes in clinical parameters achieved over the life of the project 
are maintained for 10 years. 
 
Sources for economic analyses 
 
Costs analysis 
The costs incurred in implementing the project were calculated by adding the actual cost of project 
delivery, and the estimated cost to participants of buying equipment for exercise and healthier eating, 
and the additional cost of increased use of medical services for health checks.  This did not include 
the additional costs of developing and piloting the project. 
 
Cost effectiveness analysis 
The first economic analysis undertaken was cost-effectiveness in which the SFF project was analysed 
in terms of the cost to achieve an observed change in clinical parameters. 
 
Cost utility analysis 
The second economic analysis estimated the incremental gain in participants’ quality adjusted life 
years as a result of the SFF project.  In order to explicitly compare QALYs that are gained at different 
points in time, future QALYs are ‘factored down’ so that they can be expressed in present values. 
This ‘factoring down’ is known as ‘discounting’, and is consistent with the treatment of future 
benefits and costs in all economic evaluations. 
 
Cost savings analysis 
Finally, the predicted downstream cost savings in terms of health care utilisation was calculated.  
Interventions may also result in changes in downstream health service use resulting from a change in 
disease incidence. The benefits of any downstream cost savings is in the freeing up of resources that 
can then be reallocated to yield benefits elsewhere. Where the impact on clinical outcomes occurred 
during the project itself and resource impacts were collected through participants’ responses to 
questionnaires, then the consequential effect on resource use can be estimated with some confidence. 
In this case, unit costs are derived from a range of sources including the Commonwealth Medicare 
Benefits Schedule (MBS) published charge-out rates for specific health disciplines. With regards to 
downstream cost savings beyond the lifetime of the project, while the steps and assumptions required 
in the modelling are many, and as a result estimates are both complex and uncertain, a review of the 
literature has provided estimates that can be applied to the SFF project. Future costs savings are 
‘factored down’ or ‘discounted’ so that they can be expressed in present values.  
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The Sustainable Farm Families Project 
 
Need for the project 
 
Across Australia, living in regional, rural and remote areas is associated with higher rates of avoidable 
mortality among males and females. In particular, rural populations have above average rates of 
premature mortality and death through heart disease, cancer and suicide (AIHW, 2002). In terms of 
morbidity, for example, those living in remote areas are hospitalised for diabetes at over twice the rate 
of their counterparts in metropolitan areas (AIHW, 1998). 
 
Health related behaviours are an important determinant of avoidable mortality. The possible means to 
influence health related behaviours are wide ranging and include:  
• programs to inform, educate and empower citizens and patients  
• information and training for providers  
• modification to financial incentives, for instance through taxation and subsidies or adjusting the 
level of co-payments  
• direct service provision 
• regulatory arrangements and enforcement.  
 
Each set of policies or strategies for influencing lifestyle behaviours will have cost or resource use 
implications, for individuals, the community and governments, and a level of influence on lifestyle 
behaviours and subsequent health status of individuals directly affected and for the wider community. 
 
Participants 
 
The Sustainable Farm Families (SFF) project, conducted by the Western District Health Service, 
Hamilton, is designed to influence farmers’ behaviour with respect to their family health and well 
being (Brumby et al, 2005). The SFF project is for people who have farmed for more than five years 
and are aged between 18 and 75 years. It is open to any member of a family farming business and 
participants are self-selecting. Data were collected on 128 participants in five locations: Benalla, 
Clare (SA), Hamilton, Horsham and Swan Hill.  
 
The average baseline characteristics of the participants are presented in Table 2, over page.  It shows 
that the mean baseline was above the risk threshold for body mass index (26 compared to a risk 
threshold of 25), and total cholesterol (5.5 compared to a risk threshold of 4.5 or 5.5). 
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Table 2  Average baseline characteristics of SFF participants 
 
Variable Number of participants 
(n = 128) 
Percentage of 
participants 
Male  69 54% 
Female 59 46% 
Born in Australia 121 95% 
Current smoker 5 4% 
Previous smoker 28 22% 
 Mean  Standard deviation 
Age 47  8.79 
General health score (where 1 = excellent and 5 
= poor) 
2.56 0.08 
Body mass index (kg/m2) 26.06 3.44 
Total cholesterol (mmol/L) 5.49 1.10 
Waist circumference (cm) 91.18 10.79 
Waist-hip ratio 0.89 0.09 
Blood sugar level 4.88 0.63 
Blood pressure (systolic) (mm Hg) 126.28 15.13 
Blood pressure (diastolic) (mm Hg) 79.34 9.08 
Pulse rate 72.89 9.26 
 
The numbers of participants at risk in terms of particular clinical indicators are shown in Table 3. 
 
Table 3  Participants at risk in base year in terms of particular clinical indicators 
 
Participants at risk in base year Number of 
participants 
Body mass index ≥ 25 67 
Total cholesterol level ≥ 5.5 mmol/L  45 
Total cholesterol level ≥ 4.5 mmol/L  80 
Waist-hip ratio Men > 0.90 Women > 0.80 70 
Waist circumference Women > 88 cm  Men > 102 cm 30 
Blood pressure (systolic) (mm Hg) ≥140   26 
 
 
Activities 
 
The SFF project engaged with farming families through annual workshops, newsletters and their 
industry association over three years, and participants are tracked over three years using baseline 
health data, pre and post-knowledge surveys and personal action plans. 
 
Workshop presentations and activities included the epidemiology of rural health, cardiovascular 
disease, cancer, stress, diet, farm health and safety, physical activity, diabetes, anxiety, depression, 
gender specific topics and action planning. 
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Outcomes 
 
Any change in lifestyle resulting from participation in the SFF project may potentially influence 
health in a number of ways, including indirectly and over time (through disease pathways, often 
mediated through changes in clinical parameters); directly and contemporaneously (e.g. improvement 
in sense of taste if a person stops smoking); and through externalities (e.g. adoption of safe drinking 
[alcohol] practices which can have consequences for family members and others in the community). 
 
The disease pathway is the primary focus of this evaluation. Examples of this pathway are improved 
nutrition and exercise resulting in a lower incidence of Type 2 diabetes and cardio-vascular disease, 
avoiding associated losses in quality of life and life expectancy. The sequential nature of the 
relationship between changes in behaviour and health benefits explored in this evaluation is 
represented in Figure 3 below, which also provides a summary of the outcomes considered as part of 
the behaviour-health pathway considered in this evaluation. 
 
Figure 3  Sequence of intended outcomes from the SFF project 
 
 
 
Participation 
in SFF 
project 
Behaviour 
changes 
Changes in clinical 
indicators 
Changes in 
morbidity and 
mortality 
Benefits of these 
changes 
 Self-report Measured after 1 year and 
after 2 years  
Projected changes  Estimated 
benefits  
 • Eating healthier 
food 
• More exercise 
• Safer farming 
work practices 
• Health follow 
up checks 
• Obesity-related 
indicators: 
o Waist circumference 
o Body mass index 
o Waist-hip ratio 
o Percentage of fat in 
body mass 
• Blood sugar level 
• Blood pressure 
o Systolic 
o Diastolic 
• Cholesterol level 
• Pulse rate 
• General health score 
(not measured in  
Year 2) 
Reduced risk of 
• Cardio-vascular 
event 
• Death due to 
cardio-vascular 
event 
• Diabetes 
In addition, given 
the content of the 
sessions, there are 
likely to be 
reductions in 
• Farming 
accidents 
• Cancer 
• Anxiety and 
Depression 
• Increased 
Quality 
Adjusted Life 
Years 
• Downstream 
cost savings 
 
Estimated reductions in farming accidents, cancer and mental health were not included in the 
economic evaluation, which will therefore under-estimate the impact of the SFF project. Given their 
inclusion in the program, through information provision and screening, there are likely to have been 
additional benefits in terms of these outcomes. For example, several participants, as a result of the 
screening and assessment component of the program, identified health issues in the early stages, 
including melanoma, bowel cancer, anxiety and depression. Treatment was sought, increasing the 
likelihood of a successful outcome. 
 
There are several statistically significant outcomes of the SFF project. As the SFF project is a multi-
risk factor intervention, and does not nominate a primary outcome measure of interest, changes in a 
range of parameter measures at the second and third measurement period are summarised in Table 4. 
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Table 4  Mean change in clinical parameters and risk parameters from baseline to Year 2 and 
Year 3 for all participants 
 
Change from baseline to 
Year 2 Year 3 
 
Mean 
(± Standard Error) 
Mean 
(± Standard Error) 
All participants (n=97)1   
General health score (where 1 = 
excellent and 5 = poor) 
  - 0.09 (0.78)  
Body mass index (kg/m2) - 0.25 (0.10) * - 0.27 (0.13) * 
Total cholesterol level  (mmol/L) - 0.43 (0.10) *** - 0.70 (0.09) *** 
Waist circumference (cm) - 1.16 (0.40) *** - 1.59 (0.39) *** 
Waist-hip ratio - 0.01 (0.00) *** - 0.01 (0.00) *** 
Blood sugar level - 0.06 (0.06)  0.09 (0.06)   
Blood pressure (systolic) (mm Hg) - 2.722 (1.07) * -3.39 (1.23) ** 
Blood pressure (diastolic) (mm Hg) 0.92 (0.77)  0.82 (0.83)  
Pulse rate - 0.58 (0.86)  - 0.41 (0.90)  
Significance values *** p ≤ 0.001, ** p ≤ 0.01, *p ≤ 0.05. Based on two-tailed significance tests. 
Table 5 Mean change in clinical parameters and risk parameters from baseline to year 2 and 
year 3 for those at risk 
Change from baseline to 
Year 2 Year 3 
 
Mean  
(± Standard Error) 
Mean  
(± Standard Error) 
Participants at risk in base year   
Body mass index ≥ 25 (n=67) - 0.42 (0.13) ** - 0.44 (0.16) ** 
Total cholesterol level ≥ 5.5 mmol/L 
(n=45)  
- 0.91 (0.13) *** - 1.26 (0.12) *** 
Total cholesterol level ≥ 4.5 mmol/L 
(n=80) 
- 0.59 (0.1) *** - 0.92 (0.09) *** 
Total Blood sugar level ≥ 5.5 mmol/L 
(n=13) 
- 0.62 (0.13) *** - 0.56 (0.15) ** 
Waist-hip ratio 
Men > 0.90, Women > 0.80 
(n = 70) 
- 0.015 (0.00) *** - 0.016 (0.00) *** 
Waist circumference 
Women > 88 cm , Men > 102 cm 
(n = 30) 
-3.50 (0.81) *** -3.17 (0.69) *** 
Total Blood sugar level ≥ 5.5 mmol/L 
(n=13) 
- 0.62 (0.13) *** - 0.56 (0.15) ** 
Blood pressure (systolic) (mm Hg) ≥140  
(n=26) 
-10.38 (1.44) *** - 12.5 (1.91) *** 
Significance values *** p ≤ 0.001, ** p ≤ 0.01, *p ≤ 0.05. Based on two-tailed significance tests. 
 
                                                 
1 All participants refer to those 97 for whom data were available in each year. 
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Table 6 Numbers of at risk participants reducing clinical indicators below risk thresholds 
 
Clinical indicator Number reduced below risk 
threshold 
Body mass index ≥ 25 (n=67) 19 
Total cholesterol level ≥ 5.5 mmol/L (n=45) 33 
Total cholesterol level ≥ 4.5 mmol/L (n=80) 25 
Waist-hip ratio 
Men > 0.90 
Women > 0.80 
(n = 70) 
11 
Waist circumference 
Women > 88 cm 
Men > 102 cm 
(n = 30) 
10 
Blood pressure (systolic) (mm Hg) ≥140  
(n=26) 
10 
 
Statistically significant (p ≤ 0.05) mean changes over 12 and 24 month were identified in a range of 
clinical parameters for the whole cohort, including body mass index, systolic blood pressure, total 
cholesterol level, waist circumference and waist hip ratio. Highly significant reductions were recorded 
in the latter three clinical parameters. Mean changes in clinical parameters for those participants who 
were considered ‘at risk’ in the base year were also highly statistically significant. Those at risk 
achieved greater mean reductions in all the five clinical parameters considered compared to the 
reductions of all participants. For all participants, the general health score showed a very slight, and 
not statistically significant, improvement. 
 
The relatively short follow up period (24 months), however, restricts the conclusions that can be made 
about how long the effects of the SFF project persist. The improvements in clinical indicators 
achieved in Year 2 were maintained in Year 3 and, in the case of cholesterol, increased. Comments 
from participants suggest that the third year was important in consolidating the changes, even where it 
did not increase improvements. 
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Economic Evaluation 
 
Program costs 
 
Determining costs requires an understanding and capacity to estimate the resource inputs for 
delivering the intervention in question. The range of costs considered in the evaluation of the SFF 
project is listed in Table 7 below. 
 
Table 7  Costs associated with the SFF project 
 
Cost Category Type of Costs Included 
Project delivery costs • Salaries and on costs 
• Travel and accommodation 
• Venue and food costs 
• Printing  
• Capital equipment 
Health Service Utilisation • Changes in GP and specialist visits 
during the project. 
• Downstream changes in utilisation 
 
Three categories of costs were included. Firstly, project delivery costs such as salary costs, travel 
costs (if delivering locally), accommodation if needed overnight, venue costs, printing costs and 
capital costs were calculated2. Secondly, participants’ costs related to cooking and exercise 
equipment were estimated.  Thirdly, additional costs in health service utilisation were estimated. 
 
Details on the three categories of costs are contained in Appendix A. The first, contained in Table A1, 
are the project delivery costs. Costs were obtained for a 26 participant workshop, and then adjusted to 
account for the multiple sites covered in this evaluation. Table A2 contains costs for the self-reported 
net changes in health service utilisation, and Table A3 contains costs for the self-reported changes in 
participant costs. 
 
A summary of costs is reported below. 
 
Table 8  SFF Project Costs Summary 
 
 Total Cost Average Cost Per Person 
( n = 97) 
Project Delivery Costs $105,468 $1,087 
Health Service Utilisation $14,153 $145 
Participant Costs – Cooking 
equipment  
$3,422 $35 
Participant Costs – Exercise 
equipment 
$18,164 $187 
Total $141,189 $1,456 
 
The average cost per person based on resource use depends on whether we use the number of baseline 
participants, or those 97 participants for which we have three years of data. Given that all the self 
reported participant cost data was generated at the end of the program, 97 participants are considered, 
and the average cost per person equals $1,456. 
                                                 
2 Start up costs, such as research and piloting costs, have been excluded from the analysis. 
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Cost-effectiveness analysis – clinical parameters and risk factors 
 
This section considers some intermediate measures of the performance of the SFF project. Economic 
performance is described in terms of incremental cost-effectiveness ratios (ICER) relating to changes 
in clinical parameters, and cost per additional person who eliminated a risk factor over the life of the 
SFF project. 
 
The costs of the program have been evenly split between the three parameters addressed in this 
analysis:  cholesterol, blood pressure and obesity-related indicators. 
 
The ICER per parameter point reduction is calculated as the program cost/mean parameter change. 
These have been calculated for all participants (reported in Table 6), and for those considered ‘at risk’ 
at the baseline (reported in Table 7). The relevant parameter point unit of measure will obviously 
differ, depending on which parameter is considered. For example, with regard to total cholesterol, the 
ICER measures the cost to achieve a 1 mmol/L reduction in total cholesterol, while the waist 
circumference ICER measures the cost to achieve a 1 cm reduction in waist circumference. 
 
For example, the calculations for reductions in cholesterol are as follows: 
 
Mean change (for 97 
participants) 
Total project cost A third of this cost 
(assuming the costs 
are evenly spread 
between the three sets 
of parameters) 
 
Cost to achieve 
reduction of 1 
mmol/L across all 
participants 
-0.7 mmol/L $141,189 $47,063 $67,233 
 
Using the costs estimated in section 4.3, the ICER ratios outlined in Table 9 were obtained. 
 
Table 9  Incremental cost effectiveness ratio for all participants 
 
  Incremental cost-effectiveness ratio based on 
Clinical Parameter Mean Change 
(all participants, 
 n = 97) 
A third of total 
project cost 
(assuming the costs 
are evenly spread 
between the three 
sets of parameters) 
Cost to achieve a 
one unit reduction 
in the parameter 
across all 
participants. 
Cholesterol level 
(mmol/L) 
- 0.70 $47,063 $67,233 
Blood pressure – 
systolic (mm Hg) 
- 3.39 $47,063 $13,883 
Obesity-related 
indicators 
   
Body mass index - 0.27 $47,063 $174,307 
Waist-hip ratio - 0.01 $47,063 $47,063 
Waist circumference 
(cm) 
- 1.59 $47,063 $29,599 
 
Three of the indicators related to obesity were analysed as these have been used as predictive tools in 
health estimates. 
 
Of particular interest are the changes for the participants identified as being at risk.  
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Table 10  Incremental cost effective ratio for participants at risk in base year 
 
  Incremental cost-effectiveness ratio based on 
Clinical Parameter Mean Change 
(Participants at risk in 
base year) 
A third of total project 
cost (assuming the 
costs are evenly 
spread between the 
three sets of 
parameters) 
Cost to achieve a one 
unit reduction in the 
parameter across all 
at risk participants. 
Cholesterol level ≥ 5.5 
mmol/L 
- 1.26 (n = 45) $47,063 $37,352 
Cholesterol level ≥ 4.5 
mmol/L 
- 0.92 (n=80) $47,063 $51,155 
    
Blood pressure – 
systolic (mm Hg) ≥140   
- 12.5 (n = 26) $47,063 $3,765 
    
Body mass index ≥ 25 - 0.44 (n = 67) $47,063 $106,961 
Waist-hip ratio 
Men > 0.90 
Women > 0.80 
- 0.016 (n = 70) $47,063 $29,414 
Waist circumference 
(cm) 
Women > 88 cm Men 
> 102 cm 
- 3.17 (n = 30) $47,063 $14,849 
 
Two clinical parameters, total cholesterol and waist circumference, can be considered for explanatory 
purposes. Attributing one-third of the program cost to changes in total cholesterol, we can calculate 
$66,757 per mmol/L reduction in total cholesterol for all participants. Alternatively, focusing on those 
considered at risk (those participants with total cholesterol ≥ 5.5 mmol/L at the baseline), and 
attributing one-third of the program cost to changes in total cholesterol, we can calculate $37,087 per 
mmol/L reduction in total cholesterol. 
 
Attributing one-third of the program cost to changes in waist circumference, we can calculate $29,390 
per cm reduction in waist circumference for all participants. Alternatively, focusing on those 
considered at risk, and attributing one-third of the program cost to changes in waist circumference, we 
can calculate $14,741 per cm reduction in waist circumference. 
 
Using the costs estimated previously, the following costs per risk factor eliminated were obtained (see 
Table 11). 
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Table 11  Preliminary cost effectiveness estimates of eliminating risk factors 
 
  Cost per changer based on 
Risk Factor and 
target 
Number and 
percentage of people 
who changed 
A third of total 
project cost 
(assuming the costs 
are evenly spread 
between the three 
sets of parameters) 
Cost per changer 
Blood Pressure Systolic 
(mm Hg) <140  
19 (20%) $47,063 $2,477 
    
Total cholesterol level 
(mmol/L) < 5.5 mmols  
33 (34%) $47,063 $1,426 
Total cholesterol level 
(mmol/L) < 4.5 mmols 
23 (24%) $47,063 $2,046 
    
Waist-hip ratio 
Men ≤ 0.90 
Women ≤ 0.80 
11 (11%) $47,063 $4,278 
Waist circumference 
Women ≤ 88 cm  
Men ≤ 102 cm 
10 (10%) $47,063 $4,706 
Body mass index < 25 10 (10%) $47,063 $4,706 
 
Nineteen participants with systolic blood pressure ≥ 140 mm Hg in the base year reduced their levels 
to below 140mm Hg at the conclusion of the project, resulting in a cost of $2,477 per person who 
eliminated this particular risk factor. The 33 participants with total cholesterol equal to or greater than 
5.5 mmols in the base year reduced their levels to < 5.5 mmols at the conclusion of the project, 
resulting in a cost of $1,426 per person who eliminated this particular risk factor. The three measures 
of overweight status were consistent, with 10–11 individuals eliminating this risk factor, depending 
upon which measure were used, resulting in a cost of $4,278–$4,706 per person who eliminated this 
risk factor. 
 
It should be noted that this analysis will understate the cost effectiveness of the project by including 
the cost for all participants, but only the benefits for at-risk participants. There would be additional 
benefits for the other participants. This analysis does not represent an argument for targeting the 
project to ‘at-risk’ participant, as there can be reasons for including a broader range of participants in 
the project, such as encouraging participation by not stigmatising participation. 
 
Cost-effectiveness analysis – disease incidence avoided and life 
years saved 
 
In this section, the projected effect on cardiovascular disease and Type 2 diabetes resulting from the 
statistically significant changes in total cholesterol, systolic blood pressure and body mass index over 
the life of the project are estimated, and cost effectiveness ratios relating to disease incidence avoided 
and life years saved are developed. 
 
Cardiovascular disease 
Cardiovascular disease was responsible for almost 18% of the total disease burden in Victoria in 2001 
(Victoria Department of Human Services, 2005), with ischaemic heart disease (53%) and stroke 
(29%) being the major contributors. 
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Changes in both the expected prevalence of cardiovascular disease (to capture attributable morbidity 
reductions) and the expected cumulative deaths attributable to cardiovascular disease (to capture the 
impact upon life-expectancy) as a result of participation in the SFF project were estimated, using the 
reported changes in total cholesterol and systolic blood pressure. The model relied on the four 
equations in Anderson et al (1990), derived from the Framingham Heart Study along with derived 
coefficients for each variable to estimate the change in the prevalence of cardiovascular disease and 
cardiovascular attributive deaths3. A 10-year modelling time frame is assumed. An Excel spreadsheet 
was prepared for this purpose4. Given that HDL cholesterol concentrations are not reported, we 
assume that they conform to the gender specific average (1.5 mmol/L for women, 1.2 mmol/L for 
men) and remained unchanged over the life of the project  
 
The model was run separately for female non-smokers, female smokers, male non-smokers and male 
smokers. A weighted average of these four sub-populations was then obtained. The model was run for 
Year 1 and Year 3 clinical parameters, and the difference in predicted values represented the mean 
change in the probability of a cardiovascular event and mortality, respectively. 
 
The model generates the cumulative probability of a cardiovascular event each year. Thus, a first 
cardiovascular event is interpreted as newly diagnosed cardiovascular disease and the beginning of 
management of the disease: 
• the cumulative probability represents the prevalence of cardiovascular disease by year 
• the incremental difference between the cumulative probability from year n to year n+1 can be 
interpreted as the incidence of cardiovascular disease in year n+1 
• the sum of the cumulative probabilities can be interpreted as the number of years of 
cardiovascular disease management. 
 
Table 12  Mean change in ten-year risk of cardiovascular disease events and cardiovascular 
disease mortality, by baseline total cholesterol level 
 
 All 
participants 
(n=97) 
Participants with 
total cholesterol 
above 5 mmol/L 
(n = 71) 
Participants with 
total cholesterol 
5.5 mmol/L or 
above (n= 45) 
Participants with 
total cholesterol 
above 6.5 
mmol/L (n=15) 
Average change in 
probability of 
cardiovascular 
disease event 
- 2.12% - 4.11% - 4.75% - 5.77% 
Average change in 
estimated life-years 
over 10 years.  
- 0.22% - 0.52% - 0.92% - 1.2% 
 
This method generated mortality differences that were quite modest, as expected, consistent with both 
the age profile of the participants and the modest changes in total cholesterol and systolic blood 
pressure being modelled.  Of course, the changes in morbidity due to cardiovascular disease show a 
larger response than the changes in mortality. The change in absolute risk for both outcomes increases 
as baseline cholesterol levels increase. 
 
Using the average baseline risk and changes in clinical parameters experienced by all participants, on 
average each participant faces a 2.12% reduction in the chance of having a cardiovascular disease 
event in the following 10 years, while each participant gains 0.22% of a life year over 10 years due to 
lower probability of cardiovascular disease related mortality, which is approximately 17 additional 
                                                 
3 See Appendix B. The coefficients have been reviewed in the literature, and the results are mixed. For instance Liao et al., 
1999 confirmed their relevance to the USA, but both Brindle et al., 2003 and Cappuccio et al., 2002 found that the absolute 
risk of coronary heart disease from these equations are overestimated in the USA.  
4 See Appendix D. An electronic version is available to assist with future SFF modelling, both at a participant and project 
level.  
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hours. Using the average baseline risk and changes in the clinical parameters experienced by 
participants with total cholesterol above 5.5 mmols in Year 1, on average each participant in that 
subgroup faces a 4.75% reduction in the chance of having a cardiovascular disease event in the 
following 10 years, and gains 0.92% of a life year, which is approximately 3 days and 8 hours. 
Using the costs estimated in section 4.3 and the mean changes contained Table 9, we can calculate the 
cost per cardiovascular event and mortality avoided. The results are reported in tables 11 and 12, 
respectively. 
 
Table 13  Cost effectiveness of SFF in reducing the risk of CVD events over 10 years 
 
Participants Average 
change in 
probability of 
a CVD event 
 
Total change 
in number of 
CVD events 
Cost per CVD 
event avoided, 
total cost 
attributed to 
CVD 
Cost per CVD 
event avoided, 
one-half of total 
cost attributed to 
CVD 
All participants (n = 97) - 2.12% -2.06 $68,052 $34,026 
Participants with total 
cholesterol above 5 
mmol/L (n = 71)  
- 4.11% - 2.92 $48,009 $24,004 
Participants with total 
cholesterol 5.5 mmol/L or 
above  (n = 45) 
- 4.75% - 2.14 $65,509 $32,755 
Participants with total 
cholesterol above 6.5 
mmol/L (n = 15) 
- 5.77% - 0.87 $209,237 $104,619 
 
Using the average baseline risk and changes of clinical parameters experienced by all participants, it 
is estimated that over 10 years, two cardiovascular disease events will be avoided as a result of 
involvement in the SFF project5. Using average baseline risk and changes in clinical parameters 
experienced by those participants with total cholesterol above 5 mmols in the base year, almost three 
cardiovascular events will be avoided as a result of their involvement in the SFF project. 
 
Depending upon which subgroup is considered, the cost per cardiovascular disease event avoided 
ranges from $24,004 to $104,619, assuming that one-half of total project costs are attributed to 
reducing cardiovascular disease (the other half being attributed to reducing diabetes). For example, if 
we consider the at risk subgroup (total cholesterol equal to or greater than 5.5 mmols), the cost per 
cardiovascular disease event avoided is $32,755. 
 
Table 14  Cost effectiveness of SFF in terms of life years saved 
 
Participants Mean change 
in estimated 
life years over 
10 years 
Total change 
in estimated 
life years 
over 10 
years 
Cost per life-
year gained, 
total cost 
attributed to 
CVD 
Cost per life year 
gained, one-half of 
total cost 
attributed to CVD 
All participants (n = 97) - 0.22% - 0.21 $618,164 $309,082 
Participants with total 
cholesterol above 5 mmol/L 
(n = 71)  
- 0.52% - 0.37 $379,710 $189,855 
Participants with total 
cholesterol 5.5 mmol/L  or 
above (n = 45) 
- 0.92% - 0.41 $338,620 $169,310 
Participants with total 
cholesterol above 6.5 mmol/L 
(n = 15) 
- 1.2% - 0.18 $934,593 $467,297 
                                                 
5 Calculated by multiplying the average change in probability of an event by the number of participants. 
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Consistent with the modest mortality differences, the cost per cardiovascular disease death avoided is 
significantly higher than the cost per cardiovascular disease event avoided. Taking the at risk 
subgroup (total cholesterol equal to or greater than 5.5 mmols), the SFF project generated an 
estimated incremental gain of 41.4% of a life year, and the cost per life year gained is $169,310, 
assuming that one-half of total project costs are attributed to cardiovascular disease. 
 
Type 2 diabetes mellitus 
Type 2 diabetes is the second leading cause of disease burden in males and sixth in females in 
Victoria (Victorian Government Department of Human Services, 2005). When the attributable burden 
is taken into account (diabetes increases the risk of cardiovascular disease conditions, such as 
ischaemic heart disease, stroke and peripheral vascular disease) diabetes is the top ranked cause of 
disease burden in both men and women. 
 
Using the diabetes risk score of Griffin et al (2002)6, changes in BMI were used to predict changes in 
participant risk of Type 2 diabetes for SFF project participants. The model was run separately for 
female non-smokers, female smokers, female former smokers, male non-smokers, male smokers and 
male former smokers. A weighted average of these six sub-populations was then obtained. 
 
The model was run separately for Year 1 and Year 3 clinical parameters and the difference in 
predicted values represents the mean change in the probability of an individual developing Type 2 
diabetes over the period of the project.  
 
Table 15  Cost effectiveness of SFF in reducing the risk of Type 2 diabetes 
 
Participants Mean change 
in probability 
of Type 2 
diabetes 
Total change 
in cases of 
Type 2 
diabetes 
Type 2 diabetes 
avoided, total cost 
attributed to 
diabetes 
Type 2 diabetes 
avoided, one-half of 
total cost attributed to 
diabetes 
All participants (n 
= 97) 0% 0 - - 
Participants with 
body mass index  
≥  25 (n=67) 
12% 8.04 $17,436 $8,718 
 
The model was run for various subgroups, based on participants’ BMI. Relatively low baseline risk 
and mean changes in BMI for all participants did not allow the model to generate changes in the 
probability of Type 2 diabetes. Taking the at risk subgroup, with BMI ≥  25, 8 cases of Type 2 
diabetes were avoided. The cost per case of Type 2 diabetes avoided equals $8,7187. 
 
Cost-utility analysis 
 
Overview 
Using the estimates from the section above, ‘Cost-effectiveness analysis – disease incidence avoided 
and life years saved’, disease specific mortality and morbidity avoided are now expressed in terms of 
the gain in participants’ quality adjusted life years (QALYs). This provides a measure of life years 
saved, adjusted for the health and other conditions of that life. A Quality Adjusted Life Year is a 
measure of the additional length of life produced by health interventions, adjusted for the quality of 
life. Perfect health is rated as 1; death is rated as zero; different health states are rated with reference 
to these – usually some number between 0 and 1 but a negative score for health states considered to 
be worse than death. QALYs can be added and compared – so that an intervention that leads to 10 
extra years of life rated as 0.5 in quality would produce a total outcome of 5 QALYs. These index 
numbers, reflecting the utility or strength of preference for various health states, have been sourced 
from the literature.  
                                                 
6 See Appendix C. An Excel spreadsheet has been provided to assist with future SFF modelling. See Appendix E. 
7 Calculated by dividing total project costs by the eight cases avoided. 
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By summing the QALYs gained as a result in the reduction in CVD and Type 2 diabetes, the 
incremental gains in QALYs as a result of the SFF project can then be estimated. 
 
Cardiovascular disease 
Total QALYs were estimated as the sum of years alive and without cardiovascular disease, as a result 
of both improvements in mortality and morbidity, plus years as survivors with cardiovascular disease.  
The quality adjustment index numbers for these two different health states were taken from Tengs and 
Wallace (2000)8. In order to explicitly compare QALYs that are gained at different points in time, 
future QALYs are ‘factored down’ or ‘discounted’ so that they can be expressed in present values. 
Total QALYs, both undiscounted and discounted at 5% per annum, are shown in Table 16. 
 
Table 16  Estimated QALYs gained over 10 years – cardio-vascular disease 
 
Participants Undiscounted QALYs 
gained over 10 years 
Discounted QALYs 
gained over 10 years 
All participants (n = 97) 0.74 0.57 
Participants with total cholesterol above 
5 mmol/L (n = 71)  
0.89 0.69 
Participants with total cholesterol 5.5 
mmol/L  or above (n = 45) 
0.77 0.59 
Participants with total cholesterol above 
6.5 mmol/L (n = 15) 
0.26 0.20 
It is interesting to compare these gains in QALY with the modest increases in life years gained that 
were set out in the previous section. This makes clear the importance of including the impacts upon 
quality of life from morbidity, and not just the extension of life.  
Over 10 years, the incremental gain in QALYs from the SFF program for all participants as a result of 
cardiovascular disease avoided is 0.74 undiscounted (0.57 discounted), while for those participants 
with total cholesterol above 5 mmols the incremental gain in undiscounted QALYs is 0.89, (0.69 in 
discounted QALYs).  For participants at risk, the predicted mean change was much greater than for 
the whole group, resulting in the larger absolute estimate of QALYs gained. 
Using the total project cost data, the estimated cost per QALY gained can be calculated. The results 
will depend upon the attribution of costs, and are reported in Table 17. 
Table 17  Estimated cost per QALY gained – cardiovascular disease 
 
Participants Cost per QALY gained, 
total cost attributed to 
CVD 
Cost per QALY, one-
half of total cost 
attributed to CVD 
Cost per QALY, one-
quarter of total cost 
attributed to CVD 
All participants (n = 97)  
Undiscounted 
QALYs 
$190,795 $95,398 $47,699 
Discounted 
QALYs 
$247,700 $123,850 $61,925 
Participants with total cholesterol above 5 mmol/L (n = 71)  
Undiscounted 
QALYs 
$158,639 $79,319 $39,659 
Discounted 
QALYs 
$204,622 $102,311 $51,155 
Participants with total cholesterol equal to or above 5.5 mmol/L (n = 45) 
Undiscounted 
QALYs 
$183,362 $91,681 $45,841 
Discounted 
QALYs 
$239,303 $119,652 $59,826 
    
                                                 
8 As deaths due to CVD events are a subset of CVD events, we deduct ‘years of death’ from years in which CVD events 
occurred. 
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Participants Cost per QALY gained, 
total cost attributed to 
CVD 
Cost per QALY, one-
half of total cost 
attributed to CVD 
Cost per QALY, one-
quarter of total cost 
attributed to CVD 
Participants with total cholesterol above 6.5 mmol/L (n = 15) 
Undiscounted 
QALYs 
$543,035 $271,157 $135,759 
Discounted 
QALYs 
$705,945 $352,973 $176,486 
 
Allocating half of total project costs to the reduction in the incidence of cardiovascular disease (the 
other half being allocated to diabetes reduction) the cost per undiscounted QALY gained is $95,398 
($123,850 per discounted QALY) for all participants and $79,319 per undiscounted QALY ($102,311 
per discounted QALY) for participants with total cholesterol above 5 mmols. 
 
Allocating one quarter of the total projects costs to the reduction in the incidence of cardiovascular 
disease (the rest being allocated to diabetes and to other outcomes such as reduced accidents and 
cancer), cost per undiscounted QALY gained equals $39,659 ($51,155 per discounted QALY) for this 
latter subgroup 
 
Type 2 diabetes mellitus 
We can also estimate the incremental gain in participants’ quality adjusted life years as a result of 
Type 2 diabetes mellitus avoided. Taking the eight cases of Type 2 diabetes avoided by project 
participants per year predicted by the model, and assuming that the changes in BMI achieved are 
maintained for ten years, the SFF project generates 80 Type 2 diabetes-free life years. Using the 
DiabCost (Colagiuri et al, 2003) data on complication prevalence and quality of life, the undiscounted 
incremental gain in QALYs over 10 years as a result of the SFF project equals 4.72. Using a 5% rate 
of discount, total QALYs over 10 years equal 3.64. Results for cost per incremental QALY gained are 
reported in Table 18. 
 
Table 18 Estimated cost per QALY gained – Type 2 diabetes 
 
Participants 
with body mass 
index  ≥  25 
(n=67) 
Cost per QALY 
gained, total cost 
attributed to 
diabetes 
Cost per QALY, 
one-half of total cost 
attributed to 
diabetes 
Cost per QALY, one-quarter 
of total cost attributed to 
diabetes 
Undiscounted 
QALYs $29,912 $14,956 $7,478 
Discounted 
QALYs $38,787 $19,393 $9,397 
 
Where half of the project costs are allocated to the reduced incidence of Type 2 diabetes, the cost per 
QALY gained as a result of predicted reduced incidence of Type 2 diabetes amongst SFF project 
participants is $14, 956 undiscounted and $19,393 discounted. 
 
If instead one quarter of total project costs are allocated to the incremental gain in QALYs flowing 
from the reduction in the incidence of diabetes, cost per QALY gained is $7,478 undiscounted and 
$9,397 discounted.  
 
Total QALYs Gained 
By summing the QALYs gained as a result in the reduction in cardiovascular disease and Type 2 
diabetes, the incremental gains in undiscounted QALYs over 10 years as a result of the SFF project 
sum to 5.619, while the gain in discounted QALYs equals 4.33. Cost per QALY depends upon 
assumptions regarding subgroup and attribution of costs, and is presented in Table 19 below. 
                                                 
9 The sum of the 4.72 gain from the reduction in the incidence of diabetes and the 0.89 gain from the reduction in the 
incidence of cardiovascular disease. 
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Table 19  Estimate cost per QALY gained- cardiovascular disease (participants with total 
cholesterol > 5 mmol/L, n = 71) and Type 2 diabetes (participants with BMI ≥ 25, n = 67) 
 
 Cost per QALY 
gained, total cost 
attributed to CVD 
and diabetes 
Cost per QALY, one-
half of total cost 
attributed to CVD 
and diabetes 
Cost per QALY, one-
quarter of total cost 
attributed to CVD 
and diabetes 
Undiscounted $29,912 $14,956 $7,478 
Discounted $32,607 $16,304 $8,152 
 
If half of the total costs of the SFF project are allocated to reduced incidence of cardiovascular disease 
and Type 2 diabetes, the cost per undiscounted QALY gained is $14,956, and $16,304 per discounted 
QALY gained. If instead one quarter of the total costs of the SFF project are allocated to these 
outcomes, the cost per undiscounted QALY gained is $7,478, and $8,152 per discounted QALY 
gained. 
 
A thorough search of the literature was unable to find comparable rural health risk factor projects for 
comparison, particularly where QALYs gained were reported. Drugs, however, are typically listed in 
the Pharmaceutical Benefits Scheme where cost per QALY is less than $40,000 (George et al, 2000). 
On this basis, regardless of the assumptions about cost allocation, the cost per QALY gained in the 
SFF project overall passes this performance threshold. 
 
It should be noted that under all cost allocation assumptions10, the estimated contribution of the SFF 
project to the reduction in the incidence of diabetes alone would enable the project to fall well within 
this acceptable cost per QALY range. 
 
In contrast, the estimated contribution of the SFF project to the reduction in the incidence of 
cardiovascular disease on its own would allow the SFF project to pass this performance threshold 
only under very specific assumptions (where baseline risk and clinical parameter changes of those 
participants above 5 mmols are considered, with an assumption of one quarter cost allocation, and 
where incremental QALYs gained over 10 years are undiscounted)11.  
 
Downstream cost savings 
 
Changes in downstream health service use resulting from a change in the incidence of Type 2 diabetes 
and cardiovascular disease can also be expected beyond the lifetime of the SFF project. A review of 
the literature has provided estimates of cost savings to government that can be applied to the SFF 
project. 
 
Downstream cardiovascular disease management cost savings 
Some insights into the cost of managing a person with cardiovascular disease can be derived from the 
literature. Mathers and Penm (1995) reported cardiovascular disease health care costs for Australia in 
1993–4. From Appendix C of their publication, the direct health care costs per patient with 
cardiovascular disease can be derived at approximately $811 per anum, or approximately $1,090 per 
patient per year in 2003 prices. 
                                                 
10 There are, of course, a number of reasons to assume that total project costs should not be allocated solely to changes in the 
predicted incidence of CVD and diabetes, the most of important of which is that the SFF project has generated more reported 
outcomes than changes in the expected incidence of CVD and Type 2 diabetes, such as those related to farm safety and 
cancer. 
11 Exploratory estimations, using a 15-year rather than a 10-year time horizon, generated more significant reductions in the 
incidence of CVD. There results were not reported, however, as the Anderson et al equations were based on 10 years of data. 
Furthermore, the predicted reduction in the incidence of Type 2 diabetes, itself a risk factor for CVD, was not included in the 
modelling in section 5.3.1, resulting in a potential understatement of the SFF project’s contribution to reducing the incidence 
of CVD.  
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Downstream management costs avoided were calculated by multiplying the predicted number of 
patients each year with a cardiovascular disease event by the $1,090 cost of management. Cost 
savings are extremely modest, in line with the modest change in predicted cardiovascular disease 
events.  Undiscounted, the cost savings over 10 years based on baseline risk and clinical parameter 
changes for all participants equals $2,235, and $3,172 for those with total cholesterol above 5 mmols. 
Discounted at 5%, the cost savings are $1,725 and $2,449 respectively. 
 
Downstream Type 2 diabetes management cost savings 
Two sources of data were used to estimate the downstream Type 2 diabetes costs savings. 
 
The DiabCost study (Colagiuri et al 2003) estimates the average cost of treating a person with Type 2 
diabetes is $5,325 per annum. Hospitalisation, outpatient/primary care/specialist care and medications 
each accounted for approximately 30% of total health care costs, with consumables such as insulin 
administering equipment and blood glucose testing accounting for 10%. Insulin (3%) and oral 
hypoglycaemic agents (4%) accounted for only 21% of the total costs of medication, with the 
majority of medication costs coming from non-diabetes medication such as lipid lowering and blood 
pressure lowering agents, non-steroidal anti-inflammatory drugs and anti-depressant agents. 
 
As people in ‘normal’ health still use health care for a range of conditions and illnesses unrelated to 
diabetes, these costs require adjustment. The Australian Institute of Health and Welfare have 
estimated the average health care cost per person in Australia to be $2,817 per annum (AIHW, 2002). 
Thus the incremental cost attributable to Type 2 diabetes may be considered the difference between 
these two figures, or $2,508 per patient per annum. 
 
Mathers and Penm (1995) reported diabetes related health care costs for Australia in 1993-4. The 
estimate average annual health system cost was $1,925. In 2003 dollars, this is approximately $2,587. 
While estimates based on Colagiuri et al (2003) and Mathers and Penm (1995) provide very similar 
management costs, the costs contained in Colagiuri et al were used, as they are more likely to 
accurately reflect recent treatment practice. 
 
Total downstream cost savings 
Given the predicted number of years free of Type 2 diabetes, then, assuming a discount rate of 5%, 
the SFF project results in a net cost saving of $154,929, or $1,597 person12 over ten years. This 
exceeds the total costs of the SFF service delivery. 
 
Overview of results 
 
Statistically significant (p ≤ 0.05) mean changes over 12 and 24 month were identified in a range of 
clinical parameters for all participants in the Sustainable Farm Families project, including body mass 
index, systolic blood pressure, total cholesterol level, waist circumference and waist hip ratio. 
Importantly, initial improvements in clinical parameters were maintained over the duration of the 
project. These sustained changes were used to predict changes in participant risk of cardiovascular 
disease and Type 2 diabetes mellitus. 
 
A three-stage cost-effectiveness analysis was used based on calculated project costs. Costs per 
parameter change in clinical indicator were calculated. Costs per risk factor eliminated ranged from 
$1,426 (total cholesterol) to $4,706 (weight). 
 
Using the mean changes in clinical parameters experienced by subgroups considered to be ‘at risk’, 
the cost per cardiovascular disease event avoided over 10 years was calculated at $32,755, the cost 
per CVD death avoided at $189,855, and the cost per case of Type 2 diabetes avoided at $8,718. 
 
Over 10 years, the incremental gain in discounted QALYs from the SFF program for all participants 
as a result of cardiovascular disease avoided is 0.57, while for those participants with total cholesterol 
                                                 
12 Based on the 97 participants for which complete data is available. 
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above 5 mmols the incremental gain in discounted QALYs is 0.69. The incremental gain in 
discounted QALYs from the SFF program due to the reduced incidence of Type 2 diabetes for 
participants with a BMI greater than or equal to 25 is 3.64. The total gain in discounted QALYs over 
10 years as a result of the SFF project is therefore calculated to be 4.33. 
 
If half of the total costs of the SFF project are allocated to these outcomes, the cost per discounted 
QALY gained is $16,304. If one quarter of the total costs of the SFF project are allocated to these 
outcomes, the cost per discounted QALY gained is $8,152. The SFF project therefore achieves the 
$40,000 per QALY acceptability threshold (used for decisions about pharmaceutical benefit support), 
largely due to its contribution to reduced incidence of Type 2 diabetes.  
 
These cost per QALY figures do not include downstream cost savings, and are therefore somewhat 
overstated.  Cost savings from the predicted reduced incidence of Type 2 diabetes over 10 years is 
estimated at $154,929, which exceeds the total cost of the SFF project itself.  
 
This suggests that the SFF project generates net cost savings to government. This may understate the 
cost savings, as it does not include: 
• additional cost savings to other parties due to morbidity and mortality avoided 
• potential additional cost savings from improvements in other health outcomes of participants, 
including farm safety 
• potential additional cost savings in health outcomes for participants’ families. 
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Implications 
 
This report provides evidence of sustained reductions in a range of clinical parameters of health for all 
participants in the Sustainable Farm Families project and for those participants considered at risk, as 
well as the elimination of risk factors that contribute to cardiovascular disease and Type 2 diabetes. 
One interpretation of the results is that participants’ dietary and exercise behaviour were changed 
sufficiently and retained long enough to induce clinical changes. While the research design did not 
include a control group or comparison group, evidence to support the contribution of the Sustainable 
Farm Families project to measured improvements in clinical indicators comes from the reported 
behaviour changes and the absence of convincing alternative explanations for these changes. This is 
an important finding in itself. The longer the duration of changes in physical activity and dietary 
behaviour, the more likely are interventions such as the SFF project to yield significant or substantial 
health gains and downstream benefits.  
 
The Sustainable Farm Families project achieved the $40,000 per QALY acceptability threshold 
utilised by the Australian Government for drugs on the Pharmaceutical Benefit Scheme (PBS), and 
generated net cost savings to government. On the basis of these two measures, the SFF project 
generated sufficient benefits to society and cost savings to government for it to be considered a 
worthwhile project. Of course, we recognise that in making decisions about resource allocation, 
criteria other than achieving cost effectiveness might be considered, particularly if there is a concern 
regarding distributional issues related to disparities in health outcomes between individuals in rural 
and remote areas and urban areas. 
  
The evaluation results were based on the assumptions that changes in participants’ health related 
behaviours would be maintained for 10 years, and that one half of project projects are attributed to 
changes in the incidence of Type 2 diabetes and cardiovascular disease. There is, however, no 
evidence about how long the observed changes in the participants’ clinical indicators would be 
maintained beyond the life of the project. Cost-effectiveness of the SFF project will be responsive to 
the duration of behavioural change, as well as to the proportion of project costs that are attributed to 
these outcomes. 
  
It should be noted that the cost-effectiveness of the SFF project would still be maintained provided 
that behavioural changes persist for five years. Assuming full attribution of project costs to changes in 
the incidence of Type 2 diabetes and cardiovascular disease would also see cost-effectiveness 
maintained if behavioural changes persist for 10 years. 
 
Next steps 
 
The report is intended to both inform future decision-making about the Sustainable Farm Families 
project, and to provide a methodology that can be used to evaluate future similar projects, including 
the implementation of the SFF project across new locations. By entering changes in clinical 
parameters, the spreadsheets developed as part of this evaluation can also assist to monitor participant 
level changes in the risk of Type 2 diabetes and cardiovascular disease over the life of their 
involvement in the project.  
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Recommendations 
 
Based on the findings of this report, it is recommended that: 
• Projects such as the Sustainable Farming Families project be continued and extended. 
• The methodology developed in this project be developed further and used to evaluate similar 
projects. 
• Further investigation of other health outcomes of the SFF should be documented and analysed. 
• Participants should be reassessed in five years to determine whether improvements in clinical 
indicators have been maintained and possibly to gather evidence about morbidity and mortality. 
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Appendix A Cost analysis 
 
 26 participant workshop 
Adjusted – 
Total project 
costs 
Salaries and on costs   
 
Medical Staff 
Year 1  
 2 x Staff time  - 5 days full cost recovery… Grade 4 nurses  
1 x staff member 3 days full cost recovery  
 
Year 2  
2 x Staff time  - 4 days full cost recovery… Grade 4 nurses  
1 x staff member 2 days full cost recovery 
 
Year 3  
2 x Staff time  - 4 days full cost recovery… Grade 4 nurses  
1 x staff member 2 days full cost recovery 
 
Administration 
Recruitment, administrative support and health record/mailing/ 
system support personnel, networking. Newsletters, printing by 4 
mail outs  
Year 1  - 7 days  
Year 2  - 4 days 
Year 3 - 4 days  
 
Data analysis  
Evaluation, data entry and statistical analysis by Biometrician 
Year 1 - 6 working days   
Year 2 - 4 working days 
Year 3 - 4 working days  
 
 
 
 
$3,284 
$   985 
 
 
$2,627 
$   657 
 
 
$2,627 
$   657 
 
 
 
 
 
$1,978 
$1,130 
$1,130 
 
 
 
$1,800 
$1,200 
$1,200 
 
 
 
 
$13,136 
$3,940 
 
 
$10,508 
$2628 
 
 
$10,508 
$$2628 
 
 
 
 
 
$7948 
$4520 
$4520 
 
 
 
$7200 
$4800 
$4800 
Travel and accommodation   
 
Year 1 - Accommodation etc for 3 staff for 3 nights @150.00 
Year 2 - Accommodation for 3 staff 1 night 
Year 3 - Accommodation for 3 staff 1 night  
 
 
$1,350 
$   450 
$   450 
 
 
$5400 
$1800 
$1800 
Venue and Food Costs   
 
Year 1 - Food costing $45 per person for year one ($26 day one $19 
day two) 
Year 2 - $25 per person for year two (one large day workshop only) 
Year 1 & 2-  Venue costing Average $250 per day by three days  
 
$1,170 
 
$650 
$750 
 
$4680 
 
$2600 
$3000 
Manuals   
 
Manual production (26 manuals at $45 per manual) 
  
 
$1,170 
 
$4680 
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Capital (equipment)   
 
Medical equipment testing  $250 per annum 
Set up kits  ( $2500.00)  ( one off) 
Computer, phone data projector, etc 
 
$7,000 
 
$7000 
Sub-total $32,265 $105, 468 
 
 
Table A2. Cost of net changes in participant costs 
 
Cooking Equipment  
Health Grills 12 X $89.95 
Cookbooks. 30 X $39.95 
Juicer: 3 X $149.95  
Steamer. 7 X $45 
Wok: 8 X  $25  
Mixmaster: 1 X $179  
$1079 
$1199 
$450 
$315 
$200 
$179 
Sub-total $3,422 
  
Exercise Equipment  
Exercise Balls 5 X $25  
Rowing Machine: 6 X $219  
Cycling Bike 14 X $159  
Shoes 20 X $119  
Walking Machine: 5 X $1499  
Exercise Bike 12 X $299  
Weights: 3 X $75  
Tennis Racket 2 X $49  
Exercise Mats. 2 X $50   
Golf Clubs 2 X $299   
Stretchy Band X 1 
Skipping Rope X 2 
Gym Membership X 1 
Swimming pool fees X 1 
$125 
$1314 
$2226 
$2380 
$7495 
$3588 
$225 
$98 
$100 
$598 
$0 
$0 
$0 
negligible 
negligible 
negligible 
negligible 
Sub-total $18,146 
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Table A3. Cost of net changes in service utilisation 
 
GP visits   
204 X $31.45 (level B, MBS)13 $6,415.80 
Specialist Visits  
 
Initial consultation 
66 X $74.05 
 
Subsequent Attendance 50 X 37.15 
 
$4,887.30 
 
 
$1,850 
Sub-total $14,153 
                                                 
13 While in some circumstances a Level C costing would have been appropriate, it was decided to use the lower Level B 
costing due to the potential overstatement by respondents of the impact of the SFF project on their ambulatory health care 
utilisation. 
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Appendix B Model for projecting 
morbidity and mortality associated with 
cardiovascular disease 
 
Parameters: 
(1) gender 
(2) age as LN( age) and LN(age)2 
(3) systolic blood pressure, as natural logarithm, based on average of 2 values 
(4) diastolic blood pressure, as natural logarithm, based on average of 2 values 
(5) cigarette smoking (current or quit in last year) 
(6) ratio of serum total cholesterol divided by HDL cholesterol, as natural logarithm 
(7) diabetes mellitus  
(8) left ventricular hypertrophy on ECG 
 
Composite parameters: 
(1) LN(age) and gender 
(2) LN(age)2 and gender 
(3) diabetes and gender 
(4) left ventricular hypertrophy and gender 
  
Parameter Finding Points 
gender male 0 
  female 1 
age in years   LN(age in years) 
    LN(age)2 
systolic blood pressure   LN(SBP) 
diastolic blood pressure   LN(DBP) 
cigarette smoking no 0 
  yes 1 
ratio total cholesterol to HDL 
cholesterol 
  LN(ratio) 
diabetes mellitus absent 0 
  present 1 
left ventricular hypertrophy absent 0 
  present 1 
age and gender male 0 
  female LN(age) 
LN(age)2 and gender male 0 
  female LN(age)2 
diabetes and gender male 0 
  female and nondiabetic 0 
  female and diabetic 1 
LVH and gender female 0 
  male and no LVH 0 
  male and LVH 1 
  
Outcomes: 
(1) coronary heart disease (CHD) 
(2) acute myocardial infarction 
(3) death from coronary heart disease 
(4) stroke 
(5) cardiovascular disease (CVD = coronary artery disease, AMI, stroke, peripheral vascular disease 
and congestive heart failure) 
(6) death from cardiovascular disease 
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W for coronary heart disease using systolic blood pressure = 
= (28.4441 * (points for gender)) (1.4792 * LN(age)) (14.4588 * (points for LN(age) and gender)) + 
(1.8515 * (points for LN(age) squared and gender)) (0.9119 * LN(SBP)) (0.2767 * (points for 
cigarette smoking)) (0.7181 * (points for cholesterol ratio)) (0.1759 * (points for diabetes)) (0.1999 * 
(points for diabetes and gender)) (0.5865 * (points for LVH)) + 15.5305 
  
W for AMI using systolic blood pressure = 
= (10.5109 * (points for gender)) (0.7965 * LN(age)) (5.4216 * (points for LN(age) and gender)) + 
(0.7101 * (points for LN(age) squared and gender)) (0.6623 * LN(SBP)) (0.2675 * (points for 
cigarette smoking)) (0.4277 * (points for cholesterol ratio)) (0.1534 * (points for diabetes)) (0.1165 * 
(points for diabetes and gender)) (0.1588 * (points for LVH and male)) + 11.4712 
  
W for death from coronary heart disease using systolic blood pressure = 
= (0.2332 * (points for gender)) (0.9440 * LN(age)) (0.5880 * LN(SBP)) (0.1367 * (points for 
cigarette smoking)) (0.3448 * (points for cholesterol ratio)) (0.0474 * (points for diabetes)) (0.2233 * 
(points for diabetes and gender)) (0.1237 * (points for LVH)) + 11.2889 
  
W for stroke using systolic blood pressure = 
= (0.2019* (points for gender)) (2.3741 * LN(age)) (2.4643 * LN(SBP)) (0.3914 * (points for 
cigarette smoking)) (0.0229 * (points for cholesterol ratio)) (0.3087 * (points for diabetes)) (0.2627 * 
(points for diabetes and gender)) (0.2355 * (points for LVH)) + 26.5116 
  
W for cardiovascular disease using systolic blood pressure = 
= (-1.2146 * (points for gender)) (1.8443 * LN(age)) + (0.3668 * (points for LN(age) and gender)) 
(1.4032 * LN(SBP)) (0.3899 * (points for cigarette smoking)) (0.5390 * (points for cholesterol ratio)) 
(0.3036 * (points for diabetes)) (0.1697 * (points for diabetes and gender)) (0.3362 * (points for 
LVH)) + 18.8144 
  
W for death from cardiovascular disease using systolic blood pressure = 
= (0.2243 * (points for gender)) + (8.2370 * LN(age)) (1.2109 * LN(age)2) (0.8383 * LN(SBP)) 
(0.1618 * (points for cigarette smoking)) (0.3493 * (points for cholesterol ratio)) (0.0833 * (points for 
diabetes)) (0.2067 * (points for diabetes and gender)) (0.2946 * (points for LVH)) 5.0385 
  
W for coronary heart disease using diastolic blood pressure = 
= (32.4811 * (points for gender)) (1.6346 * LN(age)) (16.4933 * (points for LN(age) and gender)) + 
(2.1059 * (points for LN(age) squared and gender)) (0.8670 * LN(DBP)) (0.2789 * (points for 
cigarette smoking)) (0.7142 * (points for cholesterol ratio)) (0.2082 * (points for diabetes)) (0.1973 * 
(points for diabetes and gender)) (0.7195 * (points for LVH)) + 15.5222 
  
W for AMI using diastolic blood pressure = 
= (5.1559 * (points for gender)) (0.9302 * LN(age)) (2.6310 * (points for LN(age) and gender)) + 
(0.3472 * (points for LN(age) squared and gender)) (0.5132 * LN(DBP)) (0.2721 * (points for 
cigarette smoking)) - (0.4228 * (points for cholesterol ratio)) (0.1764 * (points for diabetes)) (0.1184 
* (points for diabetes and gender)) (0.1702 * (points for LVH and male)) + 11.0436 
  
W for death from coronary heart disease using diastolic blood pressure = 
= (0.2619 * (points for gender)) (1.3025 * LN(age)) (0.4762 * LN(DBP)) (0.1553 * (points for 
cigarette smoking)) (0.4056 * (points for cholesterol ratio)) (0.0860 * (points for diabetes)) (0.2539 * 
(points for diabetes and gender)) (0.1591 * (points for LVH)) + 12.0963 
  
W for stroke using diastolic blood pressure = 
= (0.1558 * (points for gender)) (3.0997 * LN(age)) (1.7556 * LN(DBP)) (0.3975 * (points for 
cigarette smoking)) + (0.0297 * (points for cholesterol ratio)) (0.4047 * (points for diabetes)) (0.2506 
* (points for diabetes and gender)) (0.2801 * (points for LVH))+ 25.1067 
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W for cardiovascular disease using diastolic blood pressure = 
= (-0.8019 * (points for gender)) (2.1231 * LN(age)) + (0.2584 * (points for LN(age) and gender)) 
(1.0117* LN(DBP)) (0.3900 * (points for cigarette smoking)) (0.5365 * (points for cholesterol ratio)) 
(0.3575 * (points for diabetes)) (0.1661 * (points for diabetes and gender)) (0.3847 * (points for 
LVH)) + 17.5392 
  
W for death from cardiovascular disease using diastolic blood pressure = 
= (0.2102 * (points for gender)) + (9.5223 * LN(age)) (1.3999 * (LN(age)2) (0.5073 * LN(DBP)) 
(0.1548 * (points for cigarette smoking)) (0.3423 * (points for cholesterol ratio)) (0.1178 * (points for 
diabetes)) (0.1982 * (points for diabetes and gender)) (0.3181 * (points for LVH)) 9.0211 
 
X = (factor 1) + ((factor 2) * W) 
  
Systolic Equations Factor 1 Factor 2 
coronary heart disease 0.9145 -0.2784 
acute MI 3.4064 -0.8584 
death from coronary HD 2.9851 -0.9142 
Stroke -0.4312 0 
cardiovascular disease 0.6536 -0.2402 
death from CVD 0.8207 -0.4346 
  
  
Diastolic Equations Factor 1 Factor 2 
coronary heart disease 0.9341 -0.2825 
acute MI 3.4587 -0.8647 
death from coronary HD 2.1249 -0.6860 
Stroke -0.4212 0 
cardiovascular disease 0.6761 -0.2421 
death from CVD) 0.9076 -0.4528 
  
Y = EXP(X) 
 
Z = (LN(specified interval in years) W) / Y 
 
probability of outcome in specified years = 1 EXP((-1) * EXP(Z) 
 
 
Source: Anderson KM, Odell PM, et al. Cardiovascular disease risk profiles. Am Heart J. 121: 293-
298, 1990. 
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Appendix C Model for projecting 
morbidity associated with type 2 diabetes 
 
Parameters: 
(1) gender 
(2) antihypertensive medication 
(3) corticosteroid therapy 
(4) age in years 
(5) body mass index (BMI) 
(6) relatives with diabetes mellitus 
(7) smoking history 
  
Parameter Finding Point 
Gender male 0 
  female -0.879 
antihypertensive medication not prescribed 0 
  prescribed 1.222 
corticosteroid therapy not prescribed 0 
  prescribed 2.191 
age in years   (years) * 0.063 
body mass index < 25 0 
  >= 25 and < 27.5 0.699 
  >= 27.5 and < 30 1.97 
  >= 30 2.518 
relatives with diabetes mellitus none 0 
  parent or sibling 0.728 
  parent and sibling 0.753 
smoking history never smoked 0 
  former smoker -0.218 
  current smoker 0.855 
 
from Table 3, page 167 
  
X =SUM(points for the 7 parameters) - 6.322 
  
probability of Type 2 diabetes =1 / (1 + EXP((-1) * X)) 
  
Source: Griffin SJ, Little PS, et al. Diabetes risk score: towards earlier detection of Type 2 diabetes in 
general practice. Diabetes Metabolism Research and Reviews. 16: 164-171, 2002. 
34 
Appendix D Calculation tool for 
cardiovascular disease model 
 
Purpose: To estimate a person's risk for cardiovascular 
disease within a number of years using the equations of 
Anderson et al based on the Framingham Study (1990)
 
    
          
Conversion Enter       
Total cholesterol in mmol/L   mmol/L equals 0 mg/dL 
          
data enter       
Are you evaluating a person’s risk 
for cardiovascular disease? (Y or 
N)  enter Y or N     
gender of the person (enter M or F)  enter M or F    
age of the person in years  years of age    
systolic blood pressure reading #1  mm Hg    
systolic blood pressure reading #2  mm Hg    
diastolic blood pressure reading #1  mm Hg    
diastolic blood pressure reading #2  mm Hg    
Does the person smoke cigarettes? 
(Y or N)  enter Y or N    
total serum cholesterol in mg/dL  mg/dL   
HDL cholesterol in mg/dL  mg/dL    
Does the person have diabetes 
mellitus? (Y or N)  enter Y or N    
Does the person have left 
ventricular hypertrophy on ECG? (Y 
or N)  enter Y or N    
Risk calculated over how many 
years?  years    
          
calculate result       
data complete?       
evaluation appropriate?   
probability of outcome in the next  years       
coronary heart disease (using SBP)       
coronary heart disease (using DBP)       
AMI (using SBP)       
AMI (using DBP)       
death from CHD (using SBP)       
death from CHD (using DBP)       
stroke (using SBP)       
stroke (using DBP)       
cardiovascular disease (using SBP)       
cardiovascular disease (using DBP)       
death from CVD (using SBP)       
death from CVD (using DBP)       
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Appendix E Calculation tool for Type 2 diabetes model 
 
Purpose: To evaluate a person for risk of Type 2 diabetes mellitus using the diabetes 
risk score of Griffin et al (2002) 
  
 
Data enter         
Gender of the person (enter M or F)  enter M or F    
Age of the person in years  years of age    
Body weight in kilograms  kilograms       
Body height in meters  meters       
Has the person been prescribed anti-hypertensive medications? (Y 
or N)  
enter Y or 
N      
Is the person being treated with corticosteroids? (Y or N)  
enter Y or 
N      
Does the person have a parent with diabetes mellitus? (Y or N)  
enter Y or 
N      
Does the person have a sibling with diabetes mellitus? (Y or N)  
enter Y or 
N       
           
enter an "x" in the appropriate column to indicate the person's smoking history (give only 1 answer)     
  never smoked 
former 
smoker 
current 
smoker     
Smoking history         
            
Calculate result         
Data complete?         
Body mass index (BMI)  kilograms per meter squared  
Value of X         
Probability that the person has Type 2 diabetes         
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Glossary 
 
Benefits. Benefits can be understood in terms of: achievement of a specific short-term or long-term 
outcome, such as specific reductions in clinical indicators; achievement of outcomes expressed in terms 
of quality adjusted life years (QALYs) gained; achievement of outcomes expressed in monetary terms; 
and savings due to expenses avoided due to avoiding negative outcomes. 
 
Cost-effectiveness analysis. The relationship between program costs and a specific short-term or long-
term outcome. 
 
Cost-utility analysis. The relationship between costs and outcome expressed in terms of quality adjusted 
life years (QALYs). 
 
Cost-saving analysis. The measurement of net fiscal savings as a result of a program. 
 
Costs. Costs can be understood in terms of: financial values of the resources used, including money, in-
kind support, and time; foregone opportunities in not using these resources for other purposes; and a 
combination of the resources used and any negative outcomes.  
 
Quality adjusted life year (QALY). QALYs are a metric obtained by multiplying the number of 
calendar years of life by an index number that reflects the utility or strength of preference for the health 
state of the person involved. 
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